Agency Information Collection Activities: Proposed Collection; Comment Request, 25810-25811 [2019-11630]
Download as PDF
khammond on DSKBBV9HB2PROD with NOTICES
25810
Federal Register / Vol. 84, No. 107 / Tuesday, June 4, 2019 / Notices
strategies; (3) monitors and evaluates
programs to improve the public’s health;
and (4) ensures the agency’s scientific
credibility, reputation, and needs are
respected and supported by policy
makers, program partners, and
stakeholders.
Delete in its entirety the functional
statement for the Office of the Director
(CAQ1), and insert the following:
Office of the Director (CAQ1). (1)
Provides strategic advice to CDC
leadership on agency direction and
drives CDC towards actions to reduce
leading preventable causes of morbidity
and mortality; (2) ensures effectiveness
of policy, program, performance, and
strategy across the agency; (3) builds
capacity throughout CDC for policy,
program, performance, and strategy; (4)
leads the development and management
of policy and programmatic agendas
with federal agencies and other
organizations; (5) establishes and
maintains strategic partnerships with
key organizations and individuals
working on public health policies and
programs.
Delete in its entirety the title and
functional statement for the Office of
Health System Collaboration (CAQ12).
Delete in its entirety the functional
statement for the Policy Research,
Analysis, and Development Office
(CAQB), and insert the following:
Policy Research, Analysis, and
Development Office (CAQB). (1)
Identifies and assists CDC leadership in
informing policy at multiple levels (e.g.,
federal, state, local, global, and private
sector); (2) gathers and disseminates
knowledge about statutes, regulations,
and sub-regulatory guidance that can
increase the policy impact of CDC
programs; (3) conducts analyses,
including regulatory, legal, and
economic and develops strategies for
CDC policy priorities; (4) supports
policy implementation through the
provision of expertise, guidance,
reviews, and tools; (5) monitors and
evaluates the impact of CDC policies; (6)
builds policy analysis and development
capacity within CDC and the larger
public health community; (7) leads
CDC’s public health policy research
agenda; (8) manages selected partner
cooperative agreements and contracts
that focus on policy; and (9) incubates
innovative programs that emerge from
policy priorities identified by CDC
leadership.
Delete in its entirety the Program
Performance and Evaluation Office
(CAQD) and insert the following:
Program Performance and Evaluation
Office (CAQD). (1) Serves as an advisor
to CDC leadership on program
effectiveness to guide science, policy,
VerDate Sep<11>2014
17:16 Jun 03, 2019
Jkt 247001
and programmatic efforts; (2) provides
agency-wide direction, standards, and
technical assistance for program
planning, performance and
accountability; (3) supports the
harmonization of performance
measurement, accountability, and
program evaluation; (4) guides the
collection and analysis of economic,
performance, and accountability data;
(5) facilitates continuous improvement
based on program evaluation and
performance measurement; (6) manages
the CDC evaluation fellowship; (7)
provides economic evaluation support
to CDC leadership; (8) drives short-term
and long-term strategic program
planning; (9) supports evidence-driven
program design with expertise, analyses,
and tools; (10) promotes standardization
of shared programmatic activities to
improve efficiency; (11) coordinates
action planning for high impact
initiatives; and (12) facilitates
information sharing and collaboration
between programs and CDC leadership.
After the functional statement for the
Program Performance and Evaluation
Office (CAQD), insert the following:
Office of Population Health and
Healthcare (CAQE). (1) Engages multisectoral partners (e.g., private sector,
non-profit, transportation, housing,
healthcare providers and insurance
plans, foundations) to create
collaborative opportunities that improve
health outcomes; (2) uses data, subject
matter expertise and convening power
to inform the development of policies,
programs and tools; (3) provides agency
wide guidance on approaches and
partners that can help achieve CDC
aims; (4) builds capacity to use CDC
data analysis and interpretation
expertise to explore gaps in health
outcomes and develop population
health/healthcare solutions; and (5)
creates linkages and synergies between
CDC programs to maximize population
health impact.
Sherri A. Berger,
Chief Operating Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2019–11548 Filed 6–3–19; 8:45 am]
BILLING CODE 4160–18–P
PO 00000
Frm 00081
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifier: CMS–10697]
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Centers for Medicare &
Medicaid Services, Department of
Health and Human Services.
ACTION: Notice.
AGENCY:
The Centers for Medicare &
Medicaid Services (CMS) is announcing
an opportunity for the public to
comment on CMS’ intention to collect
information from the public. Under the
Paperwork Reduction Act of 1995 (the
PRA), federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information (including each proposed
extension or reinstatement of an existing
collection of information) and to allow
60 days for public comment on the
proposed action. Interested persons are
invited to send comments regarding our
burden estimates or any other aspect of
this collection of information, including
the necessity and utility of the proposed
information collection for the proper
performance of the agency’s functions,
the accuracy of the estimated burden,
ways to enhance the quality, utility, and
clarity of the information to be
collected, and the use of automated
collection techniques or other forms of
information technology to minimize the
information collection burden.
DATES: Comments must be received by
August 5, 2019.
ADDRESSES: When commenting, please
reference the document identifier or
OMB control number. To be assured
consideration, comments and
recommendations must be submitted in
any one of the following ways:
1. Electronically. You may send your
comments electronically to https://
www.regulations.gov. Follow the
instructions for ‘‘Comment or
Submission’’ or ‘‘More Search Options’’
to find the information collection
document(s) that are accepting
comments.
2. By regular mail. You may mail
written comments to the following
address: CMS, Office of Strategic
Operations and Regulatory Affairs,
Division of Regulations Development,
Attention: Document Identifier/OMB
Control Number ll, Room C4–26–05,
7500 Security Boulevard, Baltimore,
Maryland 21244–1850.
SUMMARY:
E:\FR\FM\04JNN1.SGM
04JNN1
Federal Register / Vol. 84, No. 107 / Tuesday, June 4, 2019 / Notices
To obtain copies of a supporting
statement and any related forms for the
proposed collection(s) summarized in
this notice, you may make your request
using one of following:
1. Access CMS’ website address at
https://www.cms.gov/Regulations-andGuidance/Legislation/
PaperworkReductionActof1995/PRAListing.html.
2. Email your request, including your
address, phone number, OMB number,
and CMS document identifier, to
Paperwork@cms.hhs.gov.
3. Call the Reports Clearance Office at
(410) 786–1326.
FOR FURTHER INFORMATION CONTACT:
William N. Parham at (410) 786–4669.
SUPPLEMENTARY INFORMATION:
Contents
This notice sets out a summary of the
use and burden associated with the
following information collections. More
detailed information can be found in
each collection’s supporting statement
and associated materials (see
ADDRESSES).
khammond on DSKBBV9HB2PROD with NOTICES
CMS–10697 Medicare Coverage of
Items and Services for Coverage With
Evidence Development
Under the PRA (44 U.S.C. 3501–
3520), federal agencies must obtain
approval from the Office of Management
and Budget (OMB) for each collection of
information they conduct or sponsor.
The term ‘‘collection of information’’ is
defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA
requires federal agencies to publish a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension or reinstatement of an existing
collection of information, before
submitting the collection to OMB for
approval. To comply with this
requirement, CMS is publishing this
notice.
Information Collection
1. Type of Information Collection
Request: New collection (Request for a
new OMB control number); Title of
Information Collection: Medicare
Coverage of Items and Services for
Coverage with Evidence Development;
Use: CED is a paradigm whereby
Medicare covers items and services on
the condition that they are furnished in
the context of approved clinical studies
or with the collection of additional
clinical data. In making coverage
decisions involving CED, CMS decides
VerDate Sep<11>2014
17:16 Jun 03, 2019
Jkt 247001
after a formal review of the medical
literature to cover an item or service
only in the context of an approved
clinical study or when additional
clinical data are collected to assess the
appropriateness of an item or service for
use with a particular beneficiary. When
an NCD requires CED under
1862(a)(1)(E), it is because the available
evidence about a particular item or
service is insufficient to support
coverage outside the context of a welldesigned clinical research study.
Sponsors could build interim analyses
and final analyses into their study
design and communicate these results to
CMS.
Section 1142 of the Act describes the
authority of the Agency for Healthcare
Research and Quality (AHRQ) to
conduct and support research on
outcomes, effectiveness, and
appropriateness of services and
procedures to identify the most effective
and appropriate means to prevent,
diagnose, treat, and manage diseases,
disorders, and other health conditions.
That section includes a requirement that
the Secretary assure that AHRQ research
priorities under Section 1142
appropriately reflect the needs and
priorities of the Medicare program.
The coordination of AHRQ priorities
under section 1142 with the needs and
priorities of the Medicare program is
accomplished through direct
collaboration between the AHRQ and
CMS. AHRQ reviews all CED NCDs
established under Section 1862(a)(1)(E)
of the Act. Consistent with section 1142,
AHRQ also indicates its support for
clinical research studies that CMS
determines address the CED questions
and meet the general standards for CED
studies. In order for CMS (or its
designated entity) to determine if the
Medicare coverage criteria are met, as
described in our regulations, CMS (or its
designated entity) must review the
study protocol and supporting
materials, as needed. Form Number:
CMS–10697 (OMB control number:
0938–New); Frequency: Yearly; Affected
Public: Private Sector (Business or other
for-profits, Not-for-Profit Institutions);
Number of Respondents: 15; Total
Annual Responses: 15; Total Annual
Hours: 15,000. (For policy questions
regarding this collection contact Xiufen
Sui at 410–786–3136.)
Dated: May 30, 2019,
William N. Parham, III,
Director, Paperwork Reduction Staff, Office
of Strategic Operations and Regulatory
Affairs.
[FR Doc. 2019–11630 Filed 6–3–19; 8:45 am]
BILLING CODE 4120–01–P
PO 00000
Frm 00082
Fmt 4703
Sfmt 4703
25811
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2019–N–1707]
Teva Pharmaceuticals USA, Inc., et al.;
Withdrawal of Approval of Five
Abbreviated New Drug Applications for
Pemoline Products
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is withdrawing
the approval of five abbreviated new
drug applications (ANDAs) for products
containing pemoline. The holders of the
applications requested withdrawal of
the applications and have waived their
opportunity for a hearing.
DATES: Approval is withdrawn as of
June 4, 2019.
FOR FURTHER INFORMATION CONTACT:
Kimberly Lehrfeld, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6226,
Silver Spring, MD 20993–0002, 301–
796–3137.
SUPPLEMENTARY INFORMATION: FDA
approved the following ANDAs for
pemoline tablets for the conditions of
use in the labeling of new drug
application (NDA) 016832, the reference
listed drug on which these ANDAs
relied:
• ANDA 075030 approved on January
29, 1999
• ANDA 075287 approved on
September 18, 2000
• ANDA 075595 approved on February
28, 2000
FDA approved the following ANDAs
for pemoline chewable tablets for the
conditions of use in the labeling of NDA
017703, the reference listed drug on
which these ANDAs relied:
• ANDA 075555 approved on February
18, 2000
• ANDA 075678 approved on July 26,
2000
SUMMARY:
On October 24, 2005, FDA issued a
Postmarket Drug Safety Information for
Healthcare Professionals
communication stating its conclusion
that the overall liver toxicity risk of
CYLERT (NDAs 016832 and 017703)
and generic pemoline products
outweighed the benefits of these
products (https://wayback.archiveit.org/7993/20171114124349/https://
www.fda.gov/DrugsDrugSafety/
PostmarketDrugSafetyInformation
forPatientsandProviders/
E:\FR\FM\04JNN1.SGM
04JNN1
Agencies
[Federal Register Volume 84, Number 107 (Tuesday, June 4, 2019)]
[Notices]
[Pages 25810-25811]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-11630]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[Document Identifier: CMS-10697]
Agency Information Collection Activities: Proposed Collection;
Comment Request
AGENCY: Centers for Medicare & Medicaid Services, Department of Health
and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Medicare & Medicaid Services (CMS) is
announcing an opportunity for the public to comment on CMS' intention
to collect information from the public. Under the Paperwork Reduction
Act of 1995 (the PRA), federal agencies are required to publish notice
in the Federal Register concerning each proposed collection of
information (including each proposed extension or reinstatement of an
existing collection of information) and to allow 60 days for public
comment on the proposed action. Interested persons are invited to send
comments regarding our burden estimates or any other aspect of this
collection of information, including the necessity and utility of the
proposed information collection for the proper performance of the
agency's functions, the accuracy of the estimated burden, ways to
enhance the quality, utility, and clarity of the information to be
collected, and the use of automated collection techniques or other
forms of information technology to minimize the information collection
burden.
DATES: Comments must be received by August 5, 2019.
ADDRESSES: When commenting, please reference the document identifier or
OMB control number. To be assured consideration, comments and
recommendations must be submitted in any one of the following ways:
1. Electronically. You may send your comments electronically to
https://www.regulations.gov. Follow the instructions for ``Comment or
Submission'' or ``More Search Options'' to find the information
collection document(s) that are accepting comments.
2. By regular mail. You may mail written comments to the following
address: CMS, Office of Strategic Operations and Regulatory Affairs,
Division of Regulations Development, Attention: Document Identifier/OMB
Control Number __, Room C4-26-05, 7500 Security Boulevard, Baltimore,
Maryland 21244-1850.
[[Page 25811]]
To obtain copies of a supporting statement and any related forms
for the proposed collection(s) summarized in this notice, you may make
your request using one of following:
1. Access CMS' website address at https://www.cms.gov/Regulations-and-Guidance/Legislation/PaperworkReductionActof1995/PRA-Listing.html.
2. Email your request, including your address, phone number, OMB
number, and CMS document identifier, to [email protected].
3. Call the Reports Clearance Office at (410) 786-1326.
FOR FURTHER INFORMATION CONTACT: William N. Parham at (410) 786-4669.
SUPPLEMENTARY INFORMATION:
Contents
This notice sets out a summary of the use and burden associated
with the following information collections. More detailed information
can be found in each collection's supporting statement and associated
materials (see ADDRESSES).
CMS-10697 Medicare Coverage of Items and Services for Coverage With
Evidence Development
Under the PRA (44 U.S.C. 3501-3520), federal agencies must obtain
approval from the Office of Management and Budget (OMB) for each
collection of information they conduct or sponsor. The term
``collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA requires federal agencies
to publish a 60-day notice in the Federal Register concerning each
proposed collection of information, including each proposed extension
or reinstatement of an existing collection of information, before
submitting the collection to OMB for approval. To comply with this
requirement, CMS is publishing this notice.
Information Collection
1. Type of Information Collection Request: New collection (Request
for a new OMB control number); Title of Information Collection:
Medicare Coverage of Items and Services for Coverage with Evidence
Development; Use: CED is a paradigm whereby Medicare covers items and
services on the condition that they are furnished in the context of
approved clinical studies or with the collection of additional clinical
data. In making coverage decisions involving CED, CMS decides after a
formal review of the medical literature to cover an item or service
only in the context of an approved clinical study or when additional
clinical data are collected to assess the appropriateness of an item or
service for use with a particular beneficiary. When an NCD requires CED
under 1862(a)(1)(E), it is because the available evidence about a
particular item or service is insufficient to support coverage outside
the context of a well-designed clinical research study. Sponsors could
build interim analyses and final analyses into their study design and
communicate these results to CMS.
Section 1142 of the Act describes the authority of the Agency for
Healthcare Research and Quality (AHRQ) to conduct and support research
on outcomes, effectiveness, and appropriateness of services and
procedures to identify the most effective and appropriate means to
prevent, diagnose, treat, and manage diseases, disorders, and other
health conditions. That section includes a requirement that the
Secretary assure that AHRQ research priorities under Section 1142
appropriately reflect the needs and priorities of the Medicare program.
The coordination of AHRQ priorities under section 1142 with the
needs and priorities of the Medicare program is accomplished through
direct collaboration between the AHRQ and CMS. AHRQ reviews all CED
NCDs established under Section 1862(a)(1)(E) of the Act. Consistent
with section 1142, AHRQ also indicates its support for clinical
research studies that CMS determines address the CED questions and meet
the general standards for CED studies. In order for CMS (or its
designated entity) to determine if the Medicare coverage criteria are
met, as described in our regulations, CMS (or its designated entity)
must review the study protocol and supporting materials, as needed.
Form Number: CMS-10697 (OMB control number: 0938-New); Frequency:
Yearly; Affected Public: Private Sector (Business or other for-profits,
Not-for-Profit Institutions); Number of Respondents: 15; Total Annual
Responses: 15; Total Annual Hours: 15,000. (For policy questions
regarding this collection contact Xiufen Sui at 410-786-3136.)
Dated: May 30, 2019,
William N. Parham, III,
Director, Paperwork Reduction Staff, Office of Strategic Operations and
Regulatory Affairs.
[FR Doc. 2019-11630 Filed 6-3-19; 8:45 am]
BILLING CODE 4120-01-P